Inspire: March 2020 with Mark Lucas – Cannasouth

Description

Join us for the March Inspire event of 2020. The first Wednesday of every month, Inspire brings a new inspirational speaker to share their story and connect like-minded people.
Inspire events are sponsored by LINK Business Brokers.

Our guest speaker is Mark Lucas, the Executive Director and Chief Executive Officer from Cannasouth. 

Mark is an experienced business manager who designs and implements operational business systems throughout Cannasouth. With strong data system DNA, Mark is a skilled manager who brings a wealth of business knowledge and experience to this role.
Mark’s business background spans 25 years. He is an entrepreneur by nature with a passion for business and has been involved in a number of businesses from initial conception through to mature, well-established companies. Mark’s key strengths include management, human resources/staff, project management, contract negotiation, sales and marketing, financial control, and business strategy.
Based in Waikato, the agricultural heartland of New Zealand, Cannasouth has established state of the art laboratories, research and cultivation facilities.
When Cannasouth listed on the NZX Main Board in June 2019 it was the first company to list via an Initial Public Offering (IPO) in over two years and is the only listed medicinal cannabis company in New Zealand.  Since listing, Cannasouth has recruited top talent to join the business, established a joint venture, Cannasouth Cultivation Limited (CCL), to grow and process cannabis, and purchased a 60% stake in Midwest Pharmaceutics NZ Limited to provide a GMP manufacturing facility for the Group.
Cannasouth’s mission is to create the foundations of a well-defined and vertically integrated medicinal cannabis business with a focus on sustainability and profitability.
 
Cannasouth’s goal is the development of next-generation cannabinoid therapeutics to support patients’ health outcomes and improve their quality of life.  Phyto-cannabinoids are remarkable compounds which interact with the human and animal endocannabinoid system and by doing so are able to provide improved health and wellbeing outcomes for patients.